Business
Alto Neuroscience Announces $120 Million Private Placement Financing
MOUNTAIN VIEW, Calif., March 16, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE") for gross proceeds of approximately $120 million, before deducting offering expenses. The financing i
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/eeea40a128b27c4a6db02eccba705bb3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ysnqUcMEgXcKLN03gwoj2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/eeea40a128b27c4a6db02eccba705bb3","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YUAdZ1A.ei.ltQuTLsU01g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/eeea40a128b27c4a6db02eccba705bb3","width":1200,"height":388}},"lazy":false},{"type":"text","content":"– Financing led by Commodore Capital with participation from new and existing biotech focused investors –","length":105,"tagName":"p","attribs":{}},{"type":"text","content":"– Alto expects to use the proceeds of the financing to support the development of ALTO-207 in Treatment Resistant Depression through a planned Phase 3 study and to a potential NDA submission –","length":198,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., March 16, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE") for gross proceeds of approximately $120 million, before deducting offering expenses. The financing is being led by Commodore Capital, with participation from new and existing institutional investors, including Dellora Investments, Driehaus Capital Management, Perceptive Advisors, Spruce Street Capital, Venrock Healthcare Capital Partners, Vestal Point Capital, and a large biotech dedicated investor.","length":839,"tagName":"p"},{"type":"text","content":"Alto intends to use the proceeds from the PIPE to fund the development of ALTO-207, a fixed-dose combination of pramipexole (a dopamine D3-preferring D3/D2 agonist) and ondansetron, through a planned Phase 3 clinical trial in treatment resistant depression ("TRD"), as well as for...